Esperion Therapeutics ESPR Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's financing cash flow?
- Esperion Therapeutics (ESPR) reported financing cash flow of $16.22M in Q1 2026.
- How has Esperion Therapeutics's financing cash flow changed year-over-year?
- Esperion Therapeutics's financing cash flow increased by 316.2% year-over-year, from -$7.5M to $16.22M.
- What is the long-term trend for Esperion Therapeutics's financing cash flow?
- Over 2 years (2021 to 2025), Esperion Therapeutics's financing cash flow has grown at a -63.3% compound annual growth rate (CAGR), from $268.22M to $36.18M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.